Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EuPCV15 in Healthy Adults
NCT04830358Phase 1Completed
- Sponsor
- EuBiologics
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of EuPCV15 in pneumococcal disease (2 arms), sponsored by EuBiologics. Primary endpoints: Incidence of Solicited Adverse Events (Local and Systemic) at 14 days, Incidence of Unsolicited Adverse Events at 28 days and 1 more. Started May 2020; status: completed.
02
Drugs
EuPCV15
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04830358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830358.